Over-expression of LPLUNC1 decreased 5-8F cell proliferation. by Yixin Yang (409184)

Vasopressin decreased the population fEPSP evoked by stimulation of LIII entorhinal fibers (EC LIII) and recorded in the CA2 dendritic field. by Magda Chafai (295116)

“…AVP (1 min) transiently decreased the LTP-potentiated fEPSP. B) Average graphs (n = 8; values expressed as % of the mean of the responses recorded during 5 min before AVP application) demonstrating that AVP (100 nM; 1 min) transiently and significantly decreased the amplitude of both S1 and S2 fEPSPs without affecting the paired-pulse facilitation (calculated as the ratio S2/S1). …”

Cdk5 inhibition by olomoucine prevents the fragmentation of the Golgi and decreases Tau secretion. by Nguyen-Vi Mohamed (323606)

The M77K mutation decreases the calcium-induced activation of Nox5. by Yusi Wang (592335)

Administration of APB5, but not APA5, decreases the hyperplasia of alveolar type 2 epithelial cells induced by BLM. by Masami Kishi (6167105)

“…The administration of APB5 markedly decreased the hyperplasia of type 2 epithelial cells induced by BLM. …”

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

Table 5_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

CD11b and TLR-5 expression are decreased on CF macrophage membrane. by Karin Simonin-Le Jeune (464354)

Identification of Gut Microbiota Biomarker Genera Distinguishing Wild and Captive Animals (A) Top 50 discriminative genera selected by random forest classifier, ranked by mean decrease accuracy. by Lin Xu (94491)

Over-expression of GAS5 decreased the expression levels of glucocorticoid-responsive genes. by Hidenori Tani (169942)

PrP^C, but not CNTN5, is decreased in sporadic AD. by Isobel J. Whitehouse (331843)

Mesothelin expression and RG7787 uptake is decreased in KLM-1-R. by Kevin Hollevoet (710450)

Ecto-5’-NT expression in D283 decreases the growth of tumor cells. by Angélica R. Cappellari (817261)

5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

Decreased levels of NMDAR2B in the synaptic plasma membrane of spinal cord of CCI-mice treated with compound 30 at 56 dpi. by Xavier Xifró (719821)

Predicted cylindrical cavity pressure as a function of saturation for two clay contents (16 and 50%) and for a range of cavity radii (1 to 5 mm). by Siul Ruiz (757454)

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”